Litcius/Paper detail

Flavonoids of <i>Salvadora persica</i> L. (meswak) and its liposomal formulation as a potential inhibitor of SARS-CoV-2

Asmaa I. Owis, Marwa S. El-Hawary, Dalia El Amir, Hesham Refaat, Eman Alaaeldin, Omar M. Aly, Mahmoud A. Elrehany, Mohamed Kamel

2021RSC Advances18 citationsDOIOpen Access PDF

Abstract

A549 cell line culture and a RT-PCR test almost as well as the FDA-approved anti-COVID-19 agent, remdesivir. Encapsulation within liposomal formulation led to a highly significant increase in the percentage of inhibition of viral replication from 38.09 ± 0.83 to 85.56 ± 1.12% in a flavonoid mixture and its liposomal preparation, respectively, and this figure approached that obtained for remdesivir (91.20 ± 1.71%). Preliminary tests were also performed, including a total flavonoid assay, a molecular docking study, a 3CL-protease inhibition assay and a cytotoxicity study. It was worthy to find a cheap, readily available, safe natural source for promising anti-SARS-CoV-2 agents, that leak their phytochemicals into the aqueous saliva during regular use as a brushing agent.

Topics & Concepts

Coronavirus disease 2019 (COVID-19)PharmacologyOutbreakTraditional medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)LiposomeChemistryMedicineVirologyInternal medicineBiochemistryDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchEssential Oils and Antimicrobial Activity
Flavonoids of <i>Salvadora persica</i> L. (meswak) and its liposomal formulation as a potential inhibitor of SARS-CoV-2 | Litcius